Literature DB >> 16985594

54-year-old woman with clitoromegaly.

Joseph A Veys, Ryan Payne, Dean G Assimos.   

Abstract

Entities:  

Year:  2004        PMID： 16985594      PMCID： PMC1472831     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  17 in total

1.  Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.

Authors:  A Haese; E Huland; M Graefen; P Hammerer; J Noldus; H Huland
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

2.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

3.  Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.

Authors:  W J Ellis; R L Vessella; J L Noteboom; P H Lange; R L Wolfert; H G Rittenhouse
Journal:  Urology       Date:  1997-10       Impact factor: 2.649

4.  Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line.

Authors:  J K Troyer; M L Beckett; G L Wright
Journal:  Prostate       Date:  1997-03-01       Impact factor: 4.104

5.  Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.

Authors:  H Yu; E P Diamandis; P Y Wong; R Nam; J Trachtenberg
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

6.  The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.

Authors:  Michael W Kattan; Shahrokh F Shariat; Ben Andrews; Kuichun Zhu; Eduardo Canto; Kazumasa Matsumoto; Masatoshi Muramoto; Peter T Scardino; Makoto Ohori; Thomas M Wheeler; Kevin M Slawin
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

7.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.

Authors:  A W Partin; J D Pearson; P K Landis; H B Carter; C R Pound; J Q Clemens; J I Epstein; P C Walsh
Journal:  Urology       Date:  1994-05       Impact factor: 2.649

8.  Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy.

Authors:  H Yu; E P Diamandis; A F Prestigiacomo; T A Stamey
Journal:  Clin Chem       Date:  1995-03       Impact factor: 8.327

9.  Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Shahrokh F Shariat; Michael J Zelefsky; Michael W Kattan; E Brian Butler; Bin S Teh; Eric A Klein; Patrick A Kupelian; Claus G Roehrborn; David A Pistenmaa; Heather D Pacholke; Stanley L Liauw; Matthew S Katz; Steven A Leibel; Peter T Scardino; Kevin M Slawin
Journal:  JAMA       Date:  2004-03-17       Impact factor: 56.272

10.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

Authors:  Anthony V D'Amico; Judd W Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen
Journal:  J Natl Cancer Inst       Date:  2003-09-17       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.